385
Participants
Start Date
March 12, 2014
Primary Completion Date
October 22, 2024
Study Completion Date
October 22, 2024
Ipilimumab
Specified dose on specified days
Nivolumab
Specified dose on specified days
Cobimetinib
Specified dose on specified days
Daratumumab
Specified dose on specified days
BMS-986016
Specified dose on specified days
Local Institution - 0022, Dublin
Local Institution - 0023, Dublin
Local Institution - 0033, Galway
Local Institution - 0019, Brussels
Local Institution - 0018, Brussels
Local Institution - 0040, Westmead
Local Institution - 0037, Melbourne
Local Institution - 0020, Leuven
Local Institution - 0039, Southport
Local Institution - 0030, Candiolo, Torino
Local Institution - 0013, Pittsburgh
Local Institution - 0041, Allentown
Local Institution - 0029, Winston-Salem
Local Institution - 0024, Durham
Local Institution - 0012, Madrid
Local Institution - 0010, Madrid
Local Institution - 0008, Atlanta
Local Institution - 0006, Nashville
Local Institution - 0011, Seville
Local Institution - 0035, Modena
Local Institution - 0034, Minneapolis
Local Institution - 0025, Paris
Local Institution - 0028, Gilbert
Local Institution - 0004, Los Angeles
Local Institution - 0001, San Francisco
Local Institution - 0005, Portland
Local Institution - 0002, Boston
Local Institution - 0036, Boston
Local Institution - 0003, Houston
Local Institution - 0027, Edmonton
Local Institution - 0016, Toronto
Local Institution - 0032, Padua
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY